N-(4-phenoxyphenyl)-2,3-dihydrothieno[3,4-b][1,4]dioxine-5-carboxamide;
2-chloro-N-(3-chlorophenyl)benzamide;
N-(3-chlorophenyl)-2-fluorobenzamide;
N-(3-chlorophenyl)-2,6-difluorobenzamide;
2,6-dichloro-N-(3-chlorophenyl)benzamide;
N-(3-chlorophenyl)-1-naphthamide;
N-(3-chlorophenyl)-2-naphthamide;
2,3-dichloro-N-(3-chlorophenyl)benzamide;
N-(3-chlorophenyl)-2,3-difluorobenzamide;
N-(3-chlorophenyl)-2,3-dimethoxybenzamide;
N-(3-chlorophenyl)benzamide;
N-(3-chlorophenyl)-2,3-dihydrobenzo[b][1,4] dioxine-5-carboxamide;
and pharmaceutically acceptable salts, solvates, prodrugs and complexes thereof.

14. A composition comprising an effective amount of at least one compound according to any one of claims 1-13.
15. The composition according to claim 14, further comprising at least one excipient.
16. A method for treating or preventing a disease that involves pregenomic RNA encapsidation, said method comprising administering to a subject an effective amount of at least one compound according to the claim 1 to treat the disease.
17. The method of claim 16 wherein the disease that involves pregenomic RNA encapsidation is HBV infection.
18. The method of claim 16, wherein the at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.
19. The method of claim 18 wherein the disease that involves pregenomic RNA encapsidation is HBV infection.
20. A method for treating or preventing disease or conditions associated with HBV infection, said method comprising administering to a subject an effective amount of at least one compound according to the claim 1 to treat the disease.
21. The method of claim 20, wherein the at least one compound is administered in a composition further comprising at least one pharmaceutically acceptable excipient.

N-(4-phenoxyphenyl)-2,3-dihydrothieno[3,4-b][1,4]dioxine-5-carboxamide;

2-chloro-N-(3-chlorophenyl)benzamide;

N-(3-chlorophenyl)-2-fluorobenzamide;

N-(3-chlorophenyl)-2,6-difluorobenzamide;

2,6-dichloro-N-(3-chlorophenyl)benzamide;

N-(3-chlorophenyl)-1-naphthamide;

N-(3-chlorophenyl)-2-naphthamide;

2,3-dichloro-N-(3-chlorophenyl)benzamide;

N-(3-chlorophenyl)-2,3-difluorobenzamide;

N-(3-chlorophenyl)-2,3-dimethoxybenzamide;

N-(3-chlorophenyl)benzamide;

N-(3-chlorophenyl)-2,3-dihydrobenzo[b][1,4] dioxine-5-carboxamide;

and pharmaceutically acceptable salts, solvates, prodrugs and complexes thereof.

14. A composition comprising an effective amount of at least one compound according to any one of claims 1-13.
15. The composition according to claim 14, further comprising at least one excipient.
16. An effective amount of at least one compound according to claim 1 for use in the treatment or prevention of a disease that involves pregenomic RNA encapsidation.
17. The compound of claim 16 wherein the disease that involves pregenomic RNA encapsidation is HBV infection.
18. The compound of claim 16, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.
19. The compound of claim 18 wherein the disease that involves pregenomic RNA encapsidation is HBV infection.
20. An effective amount of at least one compound according to claim 1 for use in the treatment or prevention of disease or conditions associated with HBV infection.
21. The compound of claim 20, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.
22. Use of an effective amount of at least one compound according to claim 1 in the manufacture of a medicament for the treatment or prevention of a disease that involves pregenomic RNA encapsidation.

23. The use of claim 22 wherein the disease that involves pregenomic RNA encapsidation is HBV infection.
24. Use of an effective amount of at least one compound according to claim 1, together with at least one pharmaceutically acceptable excipient in the manufacture of a medicament for the treatment or prevention of a disease that involves pregenomic RNA encapsidation.
25. The use of claim 24 wherein the disease that involves pregenomic RNA encapsidation is HBV infection.
26. Use of an effective amount of at least one compound according to claim 1 in the manufacture of a medicament for the treatment or prevention of disease or conditions associated with HBV infection.
27. The use of claim 26, wherein the at least one compound is to be administered in a composition further comprising at least one pharmaceutically acceptable excipient.